Rallybio Corporaton (RLYB)

$0.67 +0.01 (1.00%)
Market Cap 27.45M
Revenue (ttm) 640,000.00
Net Income (ttm) -57.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,028.13%
Debt to Equity Ratio 0.00
Volume 41,700
Avg Vol 267,440
Day's Range N/A - N/A
Shares Out 42.24M
Stochastic %K 79%
Beta -1.05
Analysts Sell
Price Target $1.00

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 859 3820
Address:
234 Church Street, Suite 1020, New Haven, United States
Investor1337
Investor1337 Dec. 4 at 8:53 PM
$RLYB took my profit from $SMX to RLYB
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 4 at 6:34 PM
$RLYB Added 10k more shares just now. Data news in the next 3 weeks. Cash position of 1.50+/share. Should be epic in the next few weeks :)
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Dec. 2 at 5:34 PM
$RLYB I am reentering. 212 took the wind out of my sails and I bowed out on a little pop afterwards. I've rebuilt my portfolio since, and am ready to lose more money here. :)
0 · Reply
Lyn30
Lyn30 Nov. 28 at 6:00 PM
$BNKK. - c series fixed at $1.08 $RLYB – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 $IVF post split 1.89M float . Smx now $58.
0 · Reply
aletz
aletz Nov. 27 at 7:06 PM
$RLYB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ Selected top 15 on this week's AI catalyst scanner
0 · Reply
Lyn30
Lyn30 Nov. 27 at 5:32 AM
$RLYB data release anytime. – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – Cash Runway Extended through 2027 – - Analyst PT $5.
0 · Reply
Lyn30
Lyn30 Nov. 27 at 1:29 AM
$RLYB I m trader not investor. But I rarely do. This one is for investment . I want $4.50 whenever it goes .
0 · Reply
Lyn30
Lyn30 Nov. 26 at 7:53 PM
$RLYB Count me. Silently loading .
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 25 at 6:45 PM
$RLYB Upped my position to 60k shares. W/ data upcoming in the next 4 weeks and company book value of 1.50/share I'm loving these cheap shares.
0 · Reply
aletz
aletz Nov. 24 at 10:10 PM
$RLYB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ Top 10 on this week's pick
0 · Reply
Latest News on RLYB
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Sep 25, 2025, 8:00 AM EDT - 2 months ago

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Jul 8, 2025, 9:44 AM EDT - 5 months ago

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Jul 8, 2025, 8:00 AM EDT - 5 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Jun 12, 2025, 8:00 AM EDT - 6 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 7 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 1:01 PM EDT - 8 months ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Apr 8, 2025, 8:00 AM EDT - 8 months ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 8:00 AM EDT - 9 months ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 10 months ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Feb 11, 2025, 8:00 AM EST - 10 months ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Jan 10, 2025, 8:00 AM EST - 11 months ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Dec 2, 2024, 8:00 AM EST - 1 year ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 27, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 25, 2024, 8:00 AM EST - 1 year ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 21, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

National Vision Releases 2023 Sustainability Report

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Rallybio to Present at Upcoming Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 17, 2024, 4:01 PM EDT - 1 year ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Apr 1, 2024, 10:05 AM EDT - 1 year ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Feb 6, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Jan 4, 2024, 8:00 AM EST - 2 years ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 20, 2023, 8:00 AM EST - 2 years ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Dec 9, 2023, 12:00 PM EST - 2 years ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 28, 2023, 7:00 AM EST - 2 years ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 8:00 AM EST - 2 years ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Rallybio to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 2 years ago

Rallybio to Present at Upcoming Investor Conferences in November

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Rallybio: Gearing Up To Be An Opportunity

Sep 15, 2023, 5:15 PM EDT - 2 years ago

Rallybio: Gearing Up To Be An Opportunity

Investor1337
Investor1337 Dec. 4 at 8:53 PM
$RLYB took my profit from $SMX to RLYB
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 4 at 6:34 PM
$RLYB Added 10k more shares just now. Data news in the next 3 weeks. Cash position of 1.50+/share. Should be epic in the next few weeks :)
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Dec. 2 at 5:34 PM
$RLYB I am reentering. 212 took the wind out of my sails and I bowed out on a little pop afterwards. I've rebuilt my portfolio since, and am ready to lose more money here. :)
0 · Reply
Lyn30
Lyn30 Nov. 28 at 6:00 PM
$BNKK. - c series fixed at $1.08 $RLYB – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 $IVF post split 1.89M float . Smx now $58.
0 · Reply
aletz
aletz Nov. 27 at 7:06 PM
$RLYB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ Selected top 15 on this week's AI catalyst scanner
0 · Reply
Lyn30
Lyn30 Nov. 27 at 5:32 AM
$RLYB data release anytime. – RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – Cash Runway Extended through 2027 – - Analyst PT $5.
0 · Reply
Lyn30
Lyn30 Nov. 27 at 1:29 AM
$RLYB I m trader not investor. But I rarely do. This one is for investment . I want $4.50 whenever it goes .
0 · Reply
Lyn30
Lyn30 Nov. 26 at 7:53 PM
$RLYB Count me. Silently loading .
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 25 at 6:45 PM
$RLYB Upped my position to 60k shares. W/ data upcoming in the next 4 weeks and company book value of 1.50/share I'm loving these cheap shares.
0 · Reply
aletz
aletz Nov. 24 at 10:10 PM
$RLYB https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ Top 10 on this week's pick
0 · Reply
joaneegell
joaneegell Nov. 24 at 2:23 PM
$RLYB Really excited for another nothing-happening day.
0 · Reply
Ed_Ng
Ed_Ng Nov. 17 at 4:23 PM
$ABCL $RLYB penny boy does penny stock. lol better to go to MGM and play black jack.
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 17 at 4:09 PM
$ABCL TO ED NG: WATCH $RLYB IT MAY BE A PENNY STOCK NOW BUT IT ONCE TRADED AT 20 DOLLARS AND ITS COMING BACK, NOT ME HOPING, ME KNOWING... I DO EXTENSIVE RESERACH, LOOK AT CASH POSITIONS, MANAGEMENT, PIPELINES ETC.. JUST WATCH.. MAYBE YOU CAN LEARN....
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 13 at 10:21 PM
$ABCL NOT GOING TO 2... ED NG needs a reality check, worst case scenerio, stock falls to 3.20 but at that level Ill double my current position. This company is not in distress, the biotech crash is way behind us, $ABCL has too many irons in the fire with possibilities of new partnerships.. BEWARE OF THE SLEEP GIANTS $RLYB $ABCL AND $RXRX
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 12 at 8:39 PM
$RLYB Added 20k more shares today.
2 · Reply
SDBiotechInvestor
SDBiotechInvestor Nov. 11 at 7:01 PM
$RLYB - near major technical breakout with C5 knockdown data within a few weeks. 50% below cash. C5 inhibition is only going to grow hotter. $AMGN $IFRX
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Nov. 11 at 4:36 PM
$RLYB - $IFRX +20% on market digesting their C5a clinical data. Topline cohort 1+2 C5 knockdown data due over next few weeks. This target is heating up in biotech.
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 11 at 4:24 PM
$RLYB Only risk is data drop in Q4, but likely will be positive. They have cash of approx 1.5/share so it seems like a safe position at these levels. I'm loading up as much as possible.
0 · Reply
storkuk
storkuk Nov. 11 at 7:50 AM
$RLYB I am confused. is this so undervalued? what are the risks here people?
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 11 at 12:57 AM
$ARTL CODING OLD $RLYB 2.67 * BELONGS TO BELOVED CHANGING BELOVEDS 2.67 $PSTV GIVING IT TO RLYB FROM THE PAST
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Nov. 10 at 12:54 PM
$RLYB - $IFRX positive C5a data this morning. Could see increased interest here. $RYLB has two C5a drugs in development, one with C5 knockdown data in Q4.
0 · Reply
makedatbread88
makedatbread88 Nov. 10 at 12:40 PM
$RLYB watching this one closely
0 · Reply